Journal
CYTOTHERAPY
Volume 21, Issue 6, Pages 581-592Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.jcyt.2018.12.006
Keywords
clinical testing of extracellular vesicles; exosomes; extracellular vesicles (EVs); extracellular vesicles therapeutics; pharmaceutical manufacturing
Categories
Funding
- Exothera - European Regional Development Fund
- Exothera - Interreg V-A Italia-Austria 2014-2020
- WISS2015 ExtraNeu - government of Salzburg State
Ask authors/readers for more resources
Extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs) may deliver therapeutic effects that are comparable to their parental cells. MSC-EVs are promising agents for the treatment of a variety of diseases. To reach the intermediate goal of clinically testing safety and efficacy of EVs, strategies should strive for efficient translation of current EV research. On the basis of our in vitro an in vivo findings regarding the biological actions of EVs and our experience in manufacturing biological stem cell therapeutics for routine use and clinical testing, we discuss strategies of manufacturing and quality control of umbilical cord-derived MSC-EVs. We introduce guidelines of good manufacturing practice and their practicability along the path from the laboratory to the patient. We present aspects of manufacturing and final product quality testing and highlight the principle of The process is the product. The approach presented in this perspective article may facilitate translational research during the development of complex biological EV-based therapeutics in a very early stage of manufacturing as well as during early clinical safety and proof-of-concept testing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available